×
Adherex Technologies EBITDA 2010-2025 | FENC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Adherex Technologies ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Adherex Technologies EBITDA 2010-2025 | FENC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Adherex Technologies ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$229.7B
Amgen (AMGN)
$153.5B
Gilead Sciences (GILD)
$149.5B
Vertex Pharmaceuticals (VRTX)
$96B
Bristol Myers Squibb (BMY)
$93.5B
CSL (CSLLY)
$83.2B
GSK (GSK)
$76.9B
Regeneron Pharmaceuticals (REGN)
$57.9B
Alnylam Pharmaceuticals (ALNY)
$57B
Argenex SE (ARGX)
$39.1B
BioNTech SE (BNTX)
$26.3B
Insmed (INSM)
$23.9B
Royalty Pharma (RPRX)
$20.3B
Biogen (BIIB)
$18.8B
Incyte (INCY)
$15.5B
Illumina (ILMN)
$14.6B
Genmab (GNMSF)
$14.3B
Genmab (GMAB)
$13.5B
Ascendis Pharma (ASND)
$12B
BioMarin Pharmaceutical (BMRN)
$10.9B
QIAGEN (QGEN)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Exelixis (EXEL)
$10.1B
Moderna (MRNA)
$9.9B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$7.9B
Halozyme Therapeutics (HALO)
$7.7B
Exact Sciences (EXAS)
$7.7B
Roivant Sciences (ROIV)
$7.6B